Duffy David M
Department of Medicine, Division of Dermatology, University of Southern California, Los Angeles, California, USA.
Dermatol Surg. 2010 Jun;36 Suppl 2:1010-25. doi: 10.1111/j.1524-4725.2009.01469.x.
Sclerotherapy is popular for the treatment of lower extremity telangiectasias and varicose and reticular veins. Although a large number of sclerosants are commonly employed, there are few data that directly compare their advantages and drawbacks.
To analyze and present the differences between sclerosants that make them more or less suitable agents in specific clinical applications.
A systemic review of published medical literature that compares and contrasts different classes of sclerosants is presented.
There is no perfect sclerosant that is complication free and 100% effective. The ability to match the sclerosant to the clinical problem being approached makes the availability of more Food and Drug Administration-approved sclerosants appealing.
Modern sclerosants that have been subjected to rigorous experimental and clinical trials will provide even more efficacious and safer patient treatments.
硬化疗法在治疗下肢毛细血管扩张、静脉曲张和网状静脉方面很受欢迎。尽管大量硬化剂被普遍使用，但直接比较它们优缺点的数据却很少。
分析并阐述硬化剂之间的差异，以便在特定临床应用中判断其适用性。
对已发表的比较和对比不同类别硬化剂的医学文献进行系统综述。
不存在无并发症且100%有效的完美硬化剂。使硬化剂与所处理的临床问题相匹配的能力使得更多获得美国食品药品监督管理局批准的硬化剂具有吸引力。
经过严格实验和临床试验的现代硬化剂将为患者提供更有效、更安全的治疗。
Zotero 插件